As mentioned above, SM17 as a humanized antibody of the IgG4/kappa isotype targets the IL-25 pathway, it could suppress T2 inflammatory response and ameliorate the AD pathology in vitro and in vivo data (143). The gene discussed is IL25; the disease is Alzheimer disease.